METHANONE, ((4S,5R)-4,5-BIS(4-CHLOROPHENYL)-2-(4-(1,1-DIMETHYLETHYL)-2-ETHOXYPHENYL)-4,5-DIHYDRO-4,5-DIMETHYL-1H-IMIDAZOL-1-YL)(4-(3-(METHYLSULFONYL)PROPYL)-1-PIPERAZINYL)-
Hematologic Neoplasms
Hoffmann-La RocheSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
137 Active assets in the Hematologic Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 OHSU Knight Cancer Institute | Phase 4 | BBB |
Cyclophosphamide National Cancer Institute (NCI) | Phase 3 | BBB |
DEXAMETHASONE City of Hope Medical Center | Phase 3 | BB |
Teclistamab Janssen Pharmaceutical K.K. | Phase 2 | BB |
Bortezomib OHSU Knight Cancer Institute | Phase 4 | BB |
View all 50 →
Same molecule, other indications
METHANONE, ((4S,5R)-4,5-BIS(4-CHLOROPHENYL)-2-(4-(1,1-DIMETHYLETHYL)-2-ETHOXYPHENYL)-4,5-DIHYDRO-4,5-DIMETHYL-1H-IMIDAZOL-1-YL)(4-(3-(METHYLSULFONYL)PROPYL)-1-PIPERAZINYL)- is also rated in:
Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, AcuteDormant
CC
Indicative ·
47 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →